Introduction {#s1}
============

Esophageal cancer (EC) is a malignant lesion formed by abnormal proliferation of esophageal squamous epithelium or glandular epithelium ([@B1], [@B2]). EC is also the main causative factor of cancer-associated death worldwide, especially in several Eastern and Southern African countries ([@B3]). In 2018, it ranked seventh in terms of incidence and sixth in mortality ([@B4]). Nowadays, the surgical treatment is still an effective treatment for EC, but the operation for the body is more traumatic, so higher immune level and nutritional status of the patients are required to tolerate the surgical trauma ([@B5]). In spite of improvement in the administration and therapies of EC patients, the overall prognosis is still very poor ([@B2]). The poor prognosis and rising incidence of EC highlight the need for improved detection and prediction methods. Meanwhile, the detection of genetic biomarkers is very expensive and inconvenient, especially for patients in developing countries ([@B6]). Therefore, there is an urgent need to develop easily accessible, cheap, and effective indicators to predict the survival outcome of EC patients, which may help to improve the individualized treatment of EC patients.

Recently, it is widely accepted that cancer patient survival is determined not only by tumor pathology but also by host factors, such as the preoperative nutritional and immunological status ([@B7]). Numerous researchers showed that nutrition and immune status were closely associated with tumor progression and prognosis, including the EC ([@B8]--[@B14]). Among them, the prognostic nutritional index (PNI), calculated by combining the serum albumin levels and the total circulating lymphocyte counts ([@B15]), can be an effective indicator for reflecting nutritional and immunological status of cancer patients. Many potential mechanisms could explain this. Albumin is an essential element for cancer patients in their nutrition transport and support especially in their body metabolism ([@B16]). Lymphocytes, originating from hematopoietic cells, which include B and T lymphocytes and their effector cells, are the key components of the adaptive immune response ([@B17]). Distinct from a single predictor, PNI combines albumin and lymphocyte counts, which represent the nutritional and immune status, can better predict the patient\'s prognosis after surgery ([@B18]). More importantly, the prognostic and clinical value of PNI in different kinds of malignant cancer has been proved with emerging evidence ([@B19]--[@B21]). Increasingly, studies about the correlation between PNI and prognosis of EC are being conducted. However, most of these studies were performed with a small sample size, and their results remain conflicting. Thus, we conducted this meta-analysis to provide more comprehensive evidence that could confirm the significant prognostic performance of PNI in EC.

Materials and Methods {#s2}
=====================

This systemic review and meta-analysis were conducted in accordance to the PRISMA statement ([@B22]).

Literature Research
-------------------

Two independent reviewers (FF and JQ) performed a systemic search in PubMed, Embase, Web of Science, and CNKI using strategies as follows: "prognostic nutritional index(abstract/title)," and "cancer or tumor or carcinoma or neoplasm or malignant or malignancy or adenocarcinoma(abstract/title)," and "esophageal or esophagus(abstract/title)." All available studies were published up to July 2019 without other special limitations, if any discordance happened, we resolved it by consensus.

In addition to searching online and in order to identify potentially eligible articles, we also hand-searched the bibliographies of review articles.

Selection Criteria and Exclusion Criteria
-----------------------------------------

As a systematic analysis, articles like single sample experiment, comments, case report, letters, review articles, and editorials were eliminated from the study. Finally, the remaining studies were carefully selected when meeting the significant criteria as follows: (a) using pathological diagnoses as a golden standard to confirm the EC; (b) the articles report the hazard ratios (HRs) or odds ratios (ORs) for evaluating the correlations of PNI and overall survival (OS), progression-free survival (PFS), or complications; (c) with full-text accessible. Any disagreement in study selection was resolved by discussion with a third reviewer.

Exclusion criteria: (a) studies that involved non-human subjects, (b) studies with no relevant data on prognostic performance, (c) studies did not provide PNI and HR or OR to evaluate the correlation between PNI and patient survival. If a potential discrepancy was detected, a blinded third reviewer was assigned to adjudicate the conflict.

Data Extraction and Quality Assessments
---------------------------------------

The parameters were extracted by two independent investigators (JQ and CC) with a standard extraction table. The listed information of the essays extracted included basic information like title, author, nationality, department, ethnicity, study design, age and gender of the samples, enrolled year, cut-off value, follow-up, management, survival analysis method, HRs, and their 95% confidence intervals (CIs) for OS, PFS, and complications.

The Newcastle--Ottawa Scale (NOS) was used to assess the quality of the included studies ([@B23]). We adopted the NOS for the quality of the cohort. The NOS rating can range from 0 to 9, and a study which received a score \>7 was considered to be of high quality.

Statistical Analysis
--------------------

Statistical analysis was performed by STATA 12.0. The relationship between the prognosis of EC patients and PNI was assessed by HR (95% CI). Heterogeneity across studies was evaluated by χ^2^ and I^2^ test. An I^2^ value of more than 50% indicated significant heterogeneity existed, where random effect model was adopted to pool data. Otherwise, fixed effect model was adopted. A value of HR (low/high PNI) more than 1 with upper limit of its 95% overlap 1 suggested low PNI was a risk of worse survival.

The stoutness of the pooled HR for OS in EC patients was validated by sensitivity analysis. Publication bias was assessed by Begg\'s test. A *p*-value of \< 0.05 suggested significant publication bias, where the influence of publication bias on the merged HR was assessed by trim-and-fill method ([@B24]).

Results {#s3}
=======

Search Results
--------------

The process of literature selection and screening was presented in [Figure 1](#F1){ref-type="fig"}. We identified a total of 114 articles through authenticated database searching. And we reviewed 104 abstracts of the studies after excluding 10 duplicate articles. Twenty-five articles were further reviewed in detail after excluding 79 articles on the basis of the relevancy assessment. Of these, one paper was excluded because of unavailability of full text; 24 full-text articles were included for eligibility. Subsequently, we eliminated papers with no extractive data (8), not observational study (1), and other types of articles including review and case report (2). Thirteen articles were included finally.

![PRISMA 2009 flow diagram. From Moher et al. ([@B25]). For more information, visit [www.prisma-statement.org](http://www.prisma-statement.org).](fonc-10-00797-g0001){#F1}

Basic Information of the Included Studies
-----------------------------------------

The basic information of the 13 eligible studies ([@B26]--[@B38]) was presented in [Table 1](#T1){ref-type="table"}. These 13 studies were published between 2002 and 2018, and the accrual period of these studies was within the 1991--2017 range which had covered a long time span. Among the involved studies, four were performed in China, seven were conducted in Japan, one study was performed in Netherlands, and one was performed in Italy. A total of 3,543 patients with a median age ranging from 61.8 to 67.1 were involved in these studies. The histological type of these studies included squamous carcinoma and adenocarcinoma with a covering TNM stage from I to IV. Four of these studies did not provide the HRs for OS ([@B26]--[@B28], [@B37]) but provide the ORs for post-operative complications instead. Two of these articles provided HRs for OS and recurrence-free survival (RFS) ([@B33], [@B34]). Additionally, based on the NOS quality assessment, all the involved studies had a score of 7 or more and one had a score of 8 typically, indicating high quality. The NOS quality assessment of these studies was shown in [Table 2](#T2){ref-type="table"}.

###### 

The main characteristics of the included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                    **Country**   **Accrual periods**   **Age (median)**   **Number of patients**   **Gender Male/female**   **Histological type**                    **TNM stage**   **PNI cut-off value**   **Follow-up (month)**   **Survival data**
  ---------------------------- ------------- --------------------- ------------------ ------------------------ ------------------------ ---------------------------------------- --------------- ----------------------- ----------------------- ------------------------------
  Li et al. ([@B20])           China         March 2016--\         65.8               154                      107/47                                                            I--III          45                                              Post-operative complications
                                             December 2017                                                                                                                                                                                       

  Nozoe et al. ([@B27])        Japan         January 1991--\       62.5               258                      221/37                                                            I--IV           46                      32                      Post-operative complications
                                             December 1998                                                                                                                                                                                       

  Han-Geurts et al. ([@B28])   Netherlands   1996--2003            62                 400                      314/86                                                                            42.8                                            Post-operative complications

  Miyazaki et al. ([@B29])     Japan         February 2004--\      65.8               192                      173/19                                                            I--IV           47.7                    26.5                    OS
                                             November 2014                                                                                                                                                                                       

  Ohira et al. ([@B30])        Japan         April 2000--\         63                 91                       74/17                    Squamous carcinoma                       IV              40                                              OS
                                             April 2013                                                                                                                                                                                          

  Fang et al. ([@B38])         China         November 2016--\      61.8               103                      81/22                    Squamous carcinoma                       I--IV           44.56                                           OS
                                             November 2017                                                                                                                                                                                       

  Chen et al. ([@B31])         China         January 2005--\                          308                      268/40                                                            I--III          45                                              OS
                                             December 2008                                                                                                                                                                                       

  Zhang et al. ([@B32])        China         October 2010--\       64                 355                      281/74                   Adenocarcinoma (Siewert type II/III)     I--IV           51.3                    52                      OS
                                             December 2011                                                                                                                                                                                       

  Urabe et al. ([@B33])        Japan         February 1999--\                         1,363                    974/389                  Adenocarcinoma                           I--IV           44.8                    63.3                    OS and RFS
                                             September 2014                                                                                                                                                                                      

  Nakatani et al. ([@B34])     Japan         January 2009--\       64.7               66                       56/10                    Squamous carcinoma                       I--IV           45                                              OS and RFS
                                             August 2015                                                                                                                                                                                         

  Matsumoto et al. ([@B35])    Japan         April 2010--\         66.5               84                       77/7                                                              I--IV           45                      34.6                    OS
                                             May 2015                                                                                                                                                                                            

  Hirahara et al. ([@B36])     Japan         January 2006--\       67.1               169                      150/19                   Squamous carcinoma                       II--IV          49.2                                            OS
                                             December 2015                                                                                                                                                                                       

  Filip et al. ([@B37])        Italy         January 2008--\       62                 167                      137/30                   Adenocarcinoma (Siewert type I and II)   I--IV                                                           Post-operative complications
                                             October 2012                                                                                                                                                                                        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*OS, overall survival; RFS, recurrence-free survival*.

###### 

The Newcastle-Ottawa Scale (NOS) quality assessment of the eligible studies.

  **Study**                                     **Selection**   **Comparability**   **Outcome**   **Total**                       
  ---------------------------- ------ --------- --------------- ------------------- ------------- ----------- ---- ---- ---- ---- ---
  Chen et al. ([@B31])         308    268/40    \*              \*                                \*          \*   \*   \*   \*   7
  Fang et al. ([@B38])         103    81/22     \*              \*                  \*            \*          \*        \*   \*   7
  Filip et al. ([@B37])        167    137/30    \*              \*                  \*                        \*   \*   \*   \*   7
  Han-Geurts et al. ([@B28])   400    314/86    \*              \*                  \*            \*               \*   \*   \*   7
  Hirahara et al. ([@B36])     169    150/19    \*              \*                  \*            \*          \*   \*        \*   7
  Li et al. ([@B20])           154    107/47    \*              \*                  \*            \*          \*   \*   \*   \*   8
  Matsumoto et al. ([@B35])    84     77/7                      \*                  \*            \*          \*   \*   \*   \*   7
  Miyazaki et al. ([@B29])     192    173/19    \*              \*                  \*            \*          \*        \*   \*   7
  Nakatani et al. ([@B34])     66     56/10                     \*                  \*            \*          \*   \*   \*   \*   7
  Nozoe et al. ([@B27])        258    221/37    \*              \*                  \*            \*               \*   \*   \*   7
  Ohira et al. ([@B30])        91     74/17                     \*                  \*            \*          \*   \*   \*   \*   7
  Urabe et al. ([@B33])        1363   974/389   \*              \*                  \*            \*               \*   \*   \*   7
  Zhang et al. ([@B32])        355    281/74    \*              \*                  \*            \*               \*   \*   \*   7

Pooling Analysis
----------------

### Correlation Between Prognostic Nutritional Index and Overall Survival in Esophageal Cancer Patients

Totally, nine studies reported OS in 2,731 EC patients. Our results showed that among the EC patients with low PNI tends to a worse OS (HR 1.14, 95% CI 0.99--1.31, *p* = 0.001; [Figure 2](#F2){ref-type="fig"}).

![Forest plot of the HR assessing the correlation between the PNI and OS in EC patients. HR, hazard ratio; EC, esophageal cancer; OS, overall survival; PNI, prognostic nutritional index.](fonc-10-00797-g0002){#F2}

### Correlation Between Prognostic Nutritional Index and Recurrence-Free Survival in Esophageal Cancer Patients

Two studies ([@B33], [@B34]) with 1,429 patients provided available data for discussing the correlation between PNI and RFS. Urabe et al. ([@B33]) analyzed the data by using univariate Cox regression analysis, and their results showed that preoperative PNI was significantly associated with RFS (HR = 0.60, 95% CI 0.46--0.78, *p* \< 0.001). Nakatani et al. ([@B34]) also agreed that the preoperative PNI was significantly associated with the RFS (HR = 2.35, 95% CI 1.11--4.96, *p* = 0.026). Although the two studies both suggested that patients with low PNI may tend to have a high post-operation recurrence rate, further researches should be needed in the future.

### Correlation Between Prognostic Nutritional Index and Post-operative Complications in Esophageal Cancer Patients

Four studies discussed the correlation between PNI and post-operative complications in EC patients ([@B26]--[@B28], [@B37]). Li et al. ([@B26]) showed that low PNI was an independent risk factor for overall post-operative complications and severe post-operative complications (OR = 2.31, 95% CI 1.058--6.821, *p* = 0.036; OR = 2.91, 95% CI 1.067--10.131, *p* = 0.040, respectively). Nozoe et al. ([@B27]) also agreed that the post-operative complications in patients with higher PNI value were significantly less than that in patients with lower PNI value (OR = 3.50, 95% CI 1.89--6.49, *p* \< 0.0001). However, Han-Geurts et al. ([@B28]) argued that preoperative PNI had limited value in predicting complications after esophageal resection (OR 0.96, 95% CI 0.91--1.01, *p* = 0.078). Although Filip et al. ([@B37]) showed an undesirable result from their study (OR 0.90, 95% CI 0.81--0.98, *p* = 0.04), they still believed PNI could be an independent risk factor for major complications. The overall HR (OR 0.95, 95% CI 0.91--1.00, *p* = 0.001) of these studies was shown in [Figure 3](#F3){ref-type="fig"}.

![Forest plot of the HR assessing the correlation between the PNI and complications in EC patients. HR, hazard ratio; EC, esophageal cancer; PNI, prognostic nutritional index.](fonc-10-00797-g0003){#F3}

Sensitivity Analysis
--------------------

The robustness of pooled results of OS in EC patients was assessed through sensitivity analysis in our study. We found that the integrated HRs for OS did not change significantly, revealing the robustness of the pooled results. The result was shown in [Figure 4](#F4){ref-type="fig"}. Because few eligible studies were reported for RFS or post-operative complications in EC patients, we did not perform the sensitivity analysis for RFS and post-operative complications in this analysis.

![Sensitivity analyses for testing the robustness of the pooled HR for OS in EC patients. HR, hazard ratio; EC, esophageal cancer; OS, overall survival.](fonc-10-00797-g0004){#F4}

Publication Bias
----------------

The Begg\'s funnel test and Egger\'s test were applied to assess the publication bias for OS in EC patients. The funnel plot of the Begg\'s test showed an asymmetry of the result, and a significant publication bias was also shown in the Egger\'s test (*p* \< 0.05). Subsequently, we used trim-and-fill method to assess the effect of publication bias on the reliability of the integrated HRs for OS ([Figure 5](#F5){ref-type="fig"}). The results showed no trimming was performed for the data, indicating that the publication bias did not essentially affect the reliability of the integrated HRs for OS. As for the correlation between PNI and RFS or post-operative complications, the publication bias was not performed in this meta-analysis because \<10 eligible studies were reported.

![Begg\'s funnel plot of publication bias for OS **(A)**; adjusted Begg\'s funnel plot from trim-and-fill analysis for HR for OS in EC patients **(B)**.](fonc-10-00797-g0005){#F5}

Discussion {#s4}
==========

Totally, 13 studies were considered into our meta-analysis. The pooled results demonstrated that EC patients with low PNI value tend to have worse survival (OS) and a high risk of cancer recurrence rate.

Certain reports have suggested that preoperative PNI is associated with survival after surgery in patients with gastric ([@B39]) and colorectal cancer ([@B40]).

In general, our results indicated that patients with poor PNI value would have a high risk of post-operation complications which would shorten the OS time of the cancer patients. Moreover, poor nutritional and immune status could make cancer patients unable to tolerate post-operative adjuvant therapy ([@B41]). As a consequence, patients abandon post-operative adjuvant therapy, which shorten the survival time and make patients have a poor quality of life. Additionally, Nozoe et al. ([@B27]) reported that low PNI also contributed to the tumor progression.

Recently, many researchers have conducted a lot of correlative clinical researches, but so far there are still no comprehensive results. We systematically searched the databases, and then we conducted a comprehensive analysis of the results. Taken together, our pooled results demonstrated that poor PNI value is a high risk for worse prognosis in EC patients after surgery. Our meta-analysis suggested that nutritional status can be assessed by PNI, and if necessary, nutritional support treatment should be actively given before surgery.

According to the forest plot of the HR assessing the correlation between the PNI and complications in EC patients, the overall result was \<1, which suggested low PNI was not a risk factor of the complications after surgery. Then we conducted a careful analysis of the results. We found that in Han et al. ([@B42]), they reported that PNI had a limited value in predicting complications following esophageal resection with the OR (OR = 0.96, 95% CI 0.91--1.01, *p* = 0.078). In Filip et al. ([@B43]), they did a multivariable analysis between PNI and major complications; they found that the OR was 0.90 (95% CI 0.81--0.90, *p* = 0.04), so they come to a conclusion that nutritional status as PNI was significantly related with the occurrence of severe complications.

On the contrary, Li et al. ([@B26]) and Nozoe et al. ([@B27]) doubtlessly reported that low PNI patients with poor PNI value would have a high risk of post-operation complications. And the ORs of the complications were 2.91 (95% CI 1.067--10.131, *p* = 0.04) and 1.70 (95% CI 1.12--2.58, *p* = 0.012), respectively. There were few researches on PNI in predicting post-operative complications in patients with EC. And Han\'s research has a larger weight in the forest plot, which affects the comprehensive analysis of the results, and may affect the reliability of the results. More well-designed relevant researches are required in the future to confirm the predictive value of PNI in post-operative complications of EC.

There have been two other meta-analyses published on the related topic before. Li et al. ([@B44]) conducted a meta-analysis with nine articles about the prognostic value of pretreatment PNI in esophageal squamous cell carcinoma. And their conclusion was that low pretreatment PNI was significantly related with OS and RFS. PNI was a reliable prognostic factor of EC, and higher stage EC had higher incidence of low PNI. Their report confirmed our research. However, their studies only focus on the esophageal squamous cell carcinoma, our research also proved the prognostic value of PNI in other types of EC (such as esophageal adenocarcinoma). In addition, in the analysis of esophageal squamous cell carcinoma, the articles we included were not exactly the same, so our conclusions are further confirmed.

Liao et al. ([@B45]) conducted a meta-analysis with 12 articles. They also reported that the lower PNI was correlated with unfavorable prognostic factor and poor prognosis in patients with EC. However, their included studies were all from eastern Asia countries; therefore, ethnic bias may exist. Our researches included Italy and Netherlands studies; this may reduce ethnic bias and make the result more reliable. Moreover, the articles we included were not exactly the same, so our conclusions are further confirmed again.

This meta-analysis has some clinical implications. Lower PNI is noteworthily associated with worse OS in EC after surgery. However, there are still many limitations ought to be considered before clinical implications. Firstly, among the included studies, the cut-off value of PNI ranged from 40 to 51.3. Most studies set the cut-off value as 45. A PNI value \>45 defined as high PNI and \<45 defined as low PNI. The cut-off values of PNI were not consistent in all the included studies, hence a consistent optimal cut-off value of PNI is needed to be determined before PNI is extensively applied for predicting the prognosis of EC patients and their clinical treatment decision. Secondly, few researches were conducted on the association between PNI and complications, whether the PNI has a good prediction performance of complications remains unknown and future well-designed researches are required to demonstrate this issue. Thirdly, since almost all of the researches were conducted in Asia, it might generate selection bias. Fourthly, since we could not obtain the more detailed original data in the included studies, we did not perform a specific subgroup analysis on the base of stage, race, surgical approach, and so on.

Conclusion {#s5}
==========

This meta-analysis indicated a high correlation between PNI and post-operative survival of EC. EC patients with low PNI value tend to have worse OS and may be at a higher risk of EC recurrence. However, more relevant researches are needed to confirm the association between PNI and post-operative complications of EC.
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